Anne-Renee Hartman

Anne-Renee Hartman has led the clinical development program for the Galleri multi-cancer early detection test, overseeing the design and execution of pivotal clinical trials including CCGA, STRIVE, and SUMMIT. Her work on cancer signal origin prediction using targeted methylation analysis has achieved over 90 percent accuracy in identifying the tissue of origin for detected cancers. Her regulatory strategy for MCED tests has established a pathway for FDA evaluation of blood-based multi-cancer screening technologies.